Imatinib and Regression of Type 2 Diabetes

Abstract

To the Editor: We report the case of a nulliparous, 70-year-old woman with long-standing type 2 diabetes mellitus who had regression of the disease during treatment of chronic myeloid leukemia with imatinib, an antineoplastic agent. Type 2 diabetes mellitus was diagnosed when the patient was 62 years of age and weighed 60 kg (body-mass index [the weight in kilograms divided by the square of the height in meters], 24.2) She was treated with diet for one year, oral agents for four years, and insulin thereafter. After the detection of leukocytosis and immature myeloid cells in the blood, chronic myeloid leukemia . . .